As a nationally-recognized member of Greenberg Traurig’s FDA regulatory team, Nick Diamond focuses his practice exclusively on federal and international legal matters for businesses and products regulated by the U.S. Food and Drug Administration (FDA), and similar regulators in other major international markets.
Nick’s regulatory practice spans research, commercialization, post-market compliance, marketing and promotion, and enforcement across all FDA-regulated products, with a primary focus on drugs, devices, and diagnostics (including digital health products). He regularly counsels clients on “high-stakes” interactions with FDA, especially involving enforcement actions. His background as a trained bioethicist, combined with his experience teaching bioethics at leading academic institutions, enhances his ability to assist companies with ethical considerations that can emerge during research and product commercialization. His international regulatory practice is enhanced by his training in public international law, and includes in-depth experience navigating life sciences and medical device issues in Canada, the Asia-Pacific, the European Union and the United Kingdom, Latin America, and the Middle East.
Nick also applies his deep federal and international regulatory experience in the context of due diligence exercises for complex domestic and cross-border corporate transactions, especially for private equity sponsors. He has led the FDA regulatory due diligence on M&A transactions with transaction values ranging from a few million dollars to over $4 billion.
Apart from his practice, Nick is a passionate educator. Since 2018, he has taught as an adjunct professor at the Georgetown University Law Center. He is also an accomplished writer whose work has been featured in leading law reviews, scholarly journals, and well-respected media publications worldwide.
Recognition & Leadership
Awards & Accolades
•Listed, The Best Lawyers in America, Health Care Law, 2026
•Listed, The Legal 500 United States, Healthcare> Service Providers, 2025